Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhanxin Yin

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Theranostics|June 3, 2014
The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE)Wenhui Ma, Jia Jia, Shengjun Wang, et al.
Cardiovascular and Interventional Radiology|October 24, 2014
Percutaneous transhepatic biliary metal stent for malignant hilar obstruction: results and predictive factors for efficacy in 159 patients from a single centerMingwu Li, Ming Bai, Xingshun Qi, et al.
Journal of Hepatology|October 12, 2010
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosisGuohong Han, Xingshun Qi, Chuangye He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinomaLei Liu, Weijuan Wang, Hui Chen, et al.
Radiology|November 13, 2012
Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single centerGuohong Han, Xingshun Qi, Wei Zhang, et al.
BMC Cancer|May 2, 2019
Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinomaEnxin Wang, Dongdong Xia, Wei Bai, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 1, 2012
Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesisXingshun Qi, Guohong Han, Chuangye He, et al.
Journal of Pediatric Gastroenterology and Nutrition|September 19, 2015
Transjugular Intrahepatic Portosystemic Shunt for Extrahepatic Portal Venous Obstruction in ChildrenYong Lv, Chuangye He, Wengang Guo, et al.
Journal of Gastroenterology and Hepatology|December 7, 2011
Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective studyXingshun Qi, Cheng Zhang, Guohong Han, et al.
Journal of Gastroenterology and Hepatology|November 12, 2019
Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational studyJiahao Fan, Qiuhe Wang, Bohan Luo, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Theranostics|June 3, 2014
The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE)Wenhui Ma, Jia Jia, Shengjun Wang, et al.
Cardiovascular and Interventional Radiology|October 24, 2014
Percutaneous transhepatic biliary metal stent for malignant hilar obstruction: results and predictive factors for efficacy in 159 patients from a single centerMingwu Li, Ming Bai, Xingshun Qi, et al.
Journal of Hepatology|October 12, 2010
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosisGuohong Han, Xingshun Qi, Chuangye He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinomaLei Liu, Weijuan Wang, Hui Chen, et al.
Radiology|November 13, 2012
Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single centerGuohong Han, Xingshun Qi, Wei Zhang, et al.
BMC Cancer|May 2, 2019
Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinomaEnxin Wang, Dongdong Xia, Wei Bai, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 1, 2012
Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesisXingshun Qi, Guohong Han, Chuangye He, et al.
Journal of Pediatric Gastroenterology and Nutrition|September 19, 2015
Transjugular Intrahepatic Portosystemic Shunt for Extrahepatic Portal Venous Obstruction in ChildrenYong Lv, Chuangye He, Wengang Guo, et al.
Journal of Gastroenterology and Hepatology|December 7, 2011
Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective studyXingshun Qi, Cheng Zhang, Guohong Han, et al.
Journal of Gastroenterology and Hepatology|November 12, 2019
Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational studyJiahao Fan, Qiuhe Wang, Bohan Luo, et al.
Pageof 7